A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Study completion date changed from estimate of May 21, 2027 to Sep 16, 2026
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 4 of 5 entries
  2. Enrollment closed, study ongoingv5 Show 4 more changesShow less
    • Study completion pushed from Apr 1, 2027 to May 21, 2027
    • Enrollment target: estimated 21 to confirmed 19
    • Primary completion date: Sep 9, 2026 to Sep 17, 2026
    • Site details revised
  3. Trial status changed: Active, Not Recruiting → Recruiting
    • Site details revised
    v4
  4. Primary completion pushed from Mar 24, 2026 to Sep 9, 2026
    • Enrollment increased: 19 → 21 participants
    • Study completion pushed from Mar 25, 2026 to Apr 1, 2027
    v3
  5. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 21 to confirmed 19
    • Study completion date: Mar 24, 2026 to Mar 25, 2026
    • Start date changed from estimate of Nov 10, 2025 to Nov 11, 2025
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
729 trials monitored
See 62 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234. This study will take place at one site in Nottingham, United Kingdom, and will enrol 21 healthy men and women aged 18-55 years.
Trial Details
NCT Number NCT07220954
Lead Sponsor AstraZeneca
Collaborators: Quotient Sciences
Conditions
(from sponsor)		 Healthy Participants
Related terms Obesity, Overweight
Enrollment 19 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov